Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

COVID-19 Convalescent Plasma Is More than Neutralizing Antibodies: A Narrative Review of Potential Beneficial and Detrimental Co-Factors
Daniele Focosi, Massimo Franchini, Liise‐anne Pirofski, et al.
Viruses (2021) Vol. 13, Iss. 8, pp. 1594-1594
Open Access | Times Cited: 40

Showing 1-25 of 40 citing articles:

COVID-19 Convalescent Plasma and Clinical Trials: Understanding Conflicting Outcomes
Daniele Focosi, Massimo Franchini, Liise-anne Pirofski, et al.
Clinical Microbiology Reviews (2022) Vol. 35, Iss. 3
Open Access | Times Cited: 91
High-titre methylene blue-treated convalescent plasma as an early treatment for outpatients with COVID-19: a randomised, placebo-controlled trial
Andrea Alemany, Pere Millat-Martínez, Marc Corbacho-Monné, et al.
The Lancet Respiratory Medicine (2022) Vol. 10, Iss. 3, pp. 278-288
Open Access | Times Cited: 78
Essential services: Quantifying the contributions of America’s pharmacists in COVID-19 clinical interventions
John D. Grabenstein
Journal of the American Pharmacists Association (2022) Vol. 62, Iss. 6, pp. 1929-1945.e1
Open Access | Times Cited: 59
Extracellular vesicles as personalized medicine
Danielle J. Beetler, Damian N. Di Florio, Katelyn A. Bruno, et al.
Molecular Aspects of Medicine (2022) Vol. 91, pp. 101155-101155
Open Access | Times Cited: 56
Convalescent plasma therapy in COVID-19: Unravelling the data using the principles of antibody therapy
Arturo Casadevall, Michael J. Joyner, Liise-anne Pirofski, et al.
Expert Review of Respiratory Medicine (2023) Vol. 17, Iss. 5, pp. 381-395
Closed Access | Times Cited: 26
Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19: an international, randomised, open-label trial
Simone Hoffmann, Eva Schrezenmeier, Maxime Desmarets, et al.
EBioMedicine (2025) Vol. 113, pp. 105613-105613
Open Access | Times Cited: 1
Estimates of actual and potential lives saved in the United States from the use of COVID-19 convalescent plasma
Quigly Dragotakes, Patrick W. Johnson, Matthew R. Buras, et al.
Proceedings of the National Academy of Sciences (2024) Vol. 121, Iss. 41
Open Access | Times Cited: 6
Bovine-derived antibodies and camelid-derived nanobodies as biotherapeutic weapons against SARS-CoV-2 and its variants: A review article
AbdulRahman A. Saied, Asmaa A. Metwally, Moses Alobo, et al.
International Journal of Surgery (2022) Vol. 98, pp. 106233-106233
Open Access | Times Cited: 23
Therapeutic antibodies for COVID-19: is a new age of IgM, IgA and bispecific antibodies coming?
Jingjing Zhang, Han Zhang, Litao Sun
mAbs (2022) Vol. 14, Iss. 1
Open Access | Times Cited: 23
Reconstituted Extracellular Vesicles from Human Platelets Decrease Viral Myocarditis in Mice
Danielle J. Beetler, Katelyn A. Bruno, Molly M. Watkins, et al.
Small (2023) Vol. 19, Iss. 49
Open Access | Times Cited: 12
Estimates of Actual and Potential Lives Saved in the United States from the use of COVID-19 Convalescent Plasma
Quigly Dragotakes, Patrick W. Johnson, Matthew R. Buras, et al.
medRxiv (Cold Spring Harbor Laboratory) (2024)
Open Access | Times Cited: 4
Post-transfusion activation of coagulation pathways during severe COVID-19 correlates with COVID-19 convalescent plasma antibody profiles
Svenja Weiß, Hung-Mo Lin, Eric Acosta, et al.
Journal of Clinical Investigation (2025) Vol. 135, Iss. 6
Open Access
The (apparent) antibody paradox in COVID-19
Rohan Ameratunga, See‐Tarn Woon, Edward Lea, et al.
Expert Review of Clinical Immunology (2022) Vol. 18, Iss. 4, pp. 335-345
Open Access | Times Cited: 15
A Clinical Update on SARS-CoV-2: Pathology and Development of Potential Inhibitors
Desh Deepak Singh, Ihn Han, Eun Ha Choi, et al.
Current Issues in Molecular Biology (2023) Vol. 45, Iss. 1, pp. 400-433
Open Access | Times Cited: 6
Exercise and Experiments of Nature
Michael J. Joyner, Chad C. Wiggins, Sarah E. Baker, et al.
Comprehensive physiology (2023), pp. 4879-4907
Closed Access | Times Cited: 6
1,7-Bis(4-hydroxyphenyl)-1,4,6-heptatrien-3-one inhibits SARS-CoV-2 by targeting the nucleocapsid protein
Yang Liu, Kuiru Sa, Wei Xu, et al.
Acta Materia Medica (2023) Vol. 2, Iss. 3
Open Access | Times Cited: 6
PEGylated Polyester Nanoparticles Trigger Adverse Events in a Large Animal Model of Trauma and in Naı̈ve Animals: Understanding Cytokine and Cellular Correlations with These Events
Nuzhat Maisha, Chhaya Kulkarni, Narendra Pandala, et al.
ACS Nano (2022) Vol. 16, Iss. 7, pp. 10566-10580
Open Access | Times Cited: 8
Correlation between Clinical Characteristics and Antibody Levels in COVID-19 Convalescent Plasma Donor Candidates
Günalp Uzun, Rebecca Müller, Karina Althaus, et al.
Viruses (2023) Vol. 15, Iss. 6, pp. 1357-1357
Open Access | Times Cited: 4
Hyperimmune Plasma and Immunoglobulins Against COVID-19: A Narrative Review
Massimo Franchini, Daniele Focosi
(2023)
Open Access | Times Cited: 4
Predictors of mortality in COVID-19 patients treated with convalescent plasma therapy
Naomi Rahimi‐Levene, Jonathan Shapira, Irma Tzur, et al.
PLoS ONE (2022) Vol. 17, Iss. 7, pp. e0271036-e0271036
Open Access | Times Cited: 6
Is there any revival of the use of plasma therapy or neutralizing convalescent antibody therapy to treat SARS-CoV-2 variants and are we rethinking preparedness plans?
Olivier Garraud, Hervé Watier
Transfusion and Apheresis Science (2023) Vol. 62, Iss. 3, pp. 103726-103726
Open Access | Times Cited: 3
COVID-19 convalescent plasma and randomized clinical trials: explaining conflicting outcomes and finding signals of efficacy
Daniele Focosi, Massimo Franchini, Liise-anne Pirofski, et al.
medRxiv (Cold Spring Harbor Laboratory) (2021)
Open Access | Times Cited: 7
Design of VA CoronavirUs Research and Efficacy Studies-1 (VA CURES-1): A double-blind, randomized placebo-controlled trial of COVID-19 convalescent plasma in hospitalized patients with early respiratory compromise
Edward N. Janoff, Sheldon T. Brown, Ilana Belitskaya‐Lévy, et al.
Contemporary Clinical Trials Communications (2023) Vol. 35, pp. 101190-101190
Open Access | Times Cited: 2
Efficient and Sustainable Platform for Preparation of a High-Quality Immunoglobulin G as an Urgent Treatment Option During Emerging Virus Outbreaks
Tihana Kurtović, Sanda Ravlić, Adela Štimac, et al.
Frontiers in Immunology (2022) Vol. 13
Open Access | Times Cited: 3
Convalescent Plasma Therapy Significantly improves the Clotting Kinetics of COVID-19 patients
Nina Nurarifah, Siti Fatonah, Herwindo Pudjo Brahmantyo, et al.
Research Journal of Pharmacy and Technology (2024), pp. 1475-1480
Closed Access
Page 1 - Next Page

Scroll to top